Skye Bioscience Inc (SKYE)
Skye Bioscience Inc. is a clinical-stage biotechnology company listed on NASDAQ under the ticker SKYE. The company is focused on developing molecules that modulate G-protein-coupled receptors, or GPCRs, for the potential treatment of obesity, overweight, and metabolic diseases. Its lead candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody designed to target cannabinoid receptor 1, a GPCR involved in metabolic regulation. The company is headquartered in San Diego, California. Formerly known as Emerald Bioscience, Inc., it adopted the Skye Bioscience name in January 2021.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Dividend Yield | Next Earnings Date | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SKYE
|
$1.66
|
-6.5% Downside
|
Fair
|
$68 3,720.2% Upside
|
Not available
|
Bargain
|
0.0%
|
November 5, 2026
|
7.571 M
|
-1.682 M
|
2.2%
|
63.4%
|
-88.5
|
76.9%
|
